Macular Degeneration, Senile Clinical Trial
Age related macular degeneration (ARMD) is a major and irreversible cause of blindness among
the elderly. The sub-retinal space, located between the retinal pigmentary epithelium (RPE)
and the external segments of the retinal photoreceptors, plays a crucial role in this
pathology. A recent epidemiologic study in the US, unpublished yet, has shown that patients
treated with the L-DOPA, developed only later an ARMD when compared to the untreated
patients.
The L-Dopa is an endogenous ligand of the GPR43 receptor, located on the RPE's cell's apical
pole.
This receptor, via several intracellular mechanisms, regulates the cell's exosomal and
endosomal pathways: it would appear that the L-DOPA, by stimulating this receptor, decreases
significantly the RPE's exosome release.
The contents of the exosomes is still uncertain, however in addition to their signalization
role, it seems they transport pro-inflammatory components, possibly helping the cellular
recruitment due to the mononuclear phagocytic systems, particularly toxic for the
photoreceptors.
The aim of this study is to validate the hypothesis stating that he L-DOPA would play a
protective role against age related macular degeneration.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04084587 -
Visual Rehabilitation Through Acoustic Biofeedback With Retimax Vision Trainer in Patients With Advanced Age-related Macular Degeneration
|
N/A | |
| Recruiting |
NCT04847635 -
Subthreshold Laser Treatment for Reticular Pseudodrusen Secondary to Age-related Macular Degeneration
|
N/A |